Skip to content
value.today

CapsoVision, Inc.

CV
$372 Mmarket cap on Oct 30, 2026
Compare
World rank
#13,850
Revenue
$14 M
For year ending December-2025
Net income
$-25 M
-186.9% margin
SEC filing
Employees
99
As of December 31, 2025
SEC filing

CapsoVision, Inc. in brief

CapsoVision, Inc. is a listed company in the Medical Devices industry, based in Saratoga, California, USA. Its market value was $372 M on 30 October 2026, which makes it the 13,850th largest listed company in the world and the 2,722nd largest in the USA on this site. In the year to December 2025 it had sales of $14 M and a net loss of $25 M. It employs about 99 people. Its shares trade under the symbol CV (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CapsoVision, Inc.

We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.

Currently, our GI-tract capsule endoscopy solution comprises our single-use CapsoCam capsule and the associated software, CapsoCloud and CapsoView. The CapsoCam capsule, with its panoramic view, acquires and stores video images in onboard memory while moving through the GI tract and the software component allows healthcare providers to view the video retrieved from the capsule by either streaming it from the cloud, where it is securely stored, anywhere at their convenience using our CapsoCloud software or downloading data from the capsule themselves and reviewing it in our CapsoView software. Our first U.S. Food and Drug Administration cleared capsule endoscopy is our small bowel capsule (the current generation of which we refer to as CapsoCam Plus), for which we received a CE Mark in 2011 and began commercial sales in Europe in 2012, subsequent to which we received 510(k) clearance in 2016 and began commercial sales in the U.S. in 2017. CapsoCam Plus is classified as a Class II device and is used to visualize the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged 2 years and above. As of December 31, 2025, our CapsoCam Plus has been used in more than 161,000 patients. For the years ended December 31, 2025 and 2024, we generated approximately $13.6 million and $11.8 million, respectively, in revenue from sales of CapsoCam Plus, an increase of approximately 15% over the prior year. Our revenue has increased in each year since we began U.S.

From the company's annual report filed with the US SEC: read the report

CapsoVision, Inc. timeline

2 events, 2006–2025
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of CapsoVision, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$100 M$201 M$301 M$402 M

World rank over time

▲ up 40 places since 2026
2026-08-01: #13938#13,93820262026-10-14: #14031#14,03120262026-10-30: #13898#13,8982026

Rank in USA: #2,816 (Aug 2026) · #2,733 (Oct 2026) · #2,726 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
26.7×
Price / book
28.1×
Free cash flow yield
-6.2%
Net margin (TTM)
-210.3%
Operating margin
-188.3%
Return on equity
-220.6%
Liabilities / assets
27.0%
Revenue growth
+15.2%
R&D / revenue
135.1%
Revenue per employee
$137 K
Profit per employee
$-256 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue $12M, net income $-20M$12MFY24Fiscal year ending Dec 2025: revenue $14M, net income $-25M$14MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$14M+15.2%$-26M$-25M-186.9%
Dec 2024$12M—$-20M$-20M-169.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-23M$0M$-23M$-1.03—
Dec 2024$-20M$0M$-20M$-9.85—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$14M
Net income, trailing 12 months
$-29M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-5M—Dec ’24Three months to Mar 2025: revenue $3M, net income $-5M$3MMar ’25Three months to Jun 2025: revenue $3M, net income $-5M$3MJun ’25Three months to Sep 2025: revenue $4M, net income $-8M$4MSep ’25Three months to Dec 2025 (from the annual report): revenue $4M, net income $-7M$4MDec ’25Three months to Mar 2026: revenue $3M, net income $-7M$3MMar ’26Three months to Jun 2026: revenue $4M, net income $-7M$4MJun ’26Three months to Sep 2026: revenue $4M, net income $-7M$4MSep ’26

Latest quarter to Sep 2026: revenue $4M (+0.8% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of CapsoVision, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$14 M
Operating income
$-26 M
Net income
$-25 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$18 M
Total liabilities
$5 M
Total equity
$13 M

As of December-2025

Top 50 institutional investors in CapsoVision, Inc.#

As of Sep 30, 2026
50 institutions held 6.2 M shares (about 11.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 11.0%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in CapsoVision, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.2,327,875+431,787 (+22.77%)4.34%$15 MNov 13, 2026
2Vanguard Capital Management LLC1,341,834+283,366 (+26.77%)2.50%$9 MNov 13, 2026
3Geode Capital Management, LLC852,669+274,187 (+47.40%)1.59%$6 MNov 6, 2026
4State Street Corp487,066+76,825 (+18.73%)0.91%$3 MNov 12, 2026
5Vanguard Fiduciary Trust Co260,901+157,271 (+151.76%)0.49%$2 MNov 13, 2026
6Vanguard Portfolio Management LLC244,546+4,121 (+1.71%)0.46%$2 MNov 13, 2026
7UBS Group AG132,651+125,354 (+1717.88%)0.25%$1 MNov 10, 2026
8Charles Schwab Investment Management Inc85,040+5,680 (+7.16%)0.16%$1 MNov 16, 2026
9Bank of New York Mellon Corp75,387+366 (+0.49%)0.14%$0 MNov 5, 2026
10Goldman Sachs Group Inc65,022+46,395 (+249.07%)0.12%$0 MNov 16, 2026
11Nuveen, LLC46,080+69 (+0.15%)0.09%$0 MNov 10, 2026
12Bank Of America Corp /de/39,470+14,001 (+54.97%)0.07%$0 MNov 16, 2026
13Rhumbline Advisers37,939+15,970 (+72.69%)0.07%$0 MNov 10, 2026
14Deutsche Bank AG\30,451-4,249 (-12.24%)0.06%$0 MNov 6, 2026
15Price T Rowe Associates Inc /MD/29,0260 (0.00%)0.05%$0 MNov 16, 2026
16Morgan Stanley23,917+5,194 (+27.74%)0.04%$0 MNov 13, 2026
17Barclays PLC19,796+8,000 (+67.82%)0.04%$0 MNov 6, 2026
18Invesco Ltd.19,096+269 (+1.43%)0.04%$0 MNov 12, 2026
19Jpmorgan Chase & Co17,227+2,661 (+18.27%)0.03%$0 MNov 12, 2026
20MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.16,918+854 (+5.32%)0.03%$0 MNov 16, 2026
21MetLife Investment Management, LLC13,092-8,022 (-37.99%)0.02%$0 MNov 16, 2026
22Russell Investments Group, Ltd.12,419-2,030 (-14.05%)0.02%$0 MNov 6, 2026
23Vanguard Global Advisers, LLC11,317+8,777 (+345.55%)0.02%$0 MNov 13, 2026
24Wells Fargo & Company/mn10,600-21,220 (-66.69%)0.02%$0 MNov 16, 2026
25BNP Paribas Financial Markets8,797+3,223 (+57.82%)0.02%$0 MNov 12, 2026
Show all 50: investors 26 to 50
Institutional investors 26 to 50 in CapsoVision, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Police & Firemen's Retirement System of New Jersey7,185-6,092 (-45.88%)0.01%$0 MNov 9, 2026
27New York State Common Retirement Fund7,1140 (0.00%)0.01%$0 MNov 17, 2026
28Legal & General Group Plc3,3970 (0.00%)0.01%$0 MNov 16, 2026
29Tower Research Capital LLC (TRC)2,564+82 (+3.30%)0.00%$0 MNov 16, 2026
30Ameritas Investment Partners, Inc.2,2790 (0.00%)0.00%$0 MNov 13, 2026
31Royal Bank Of Canada2,209+643 (+41.06%)0.00%$0 MNov 16, 2026
32Citigroup Inc1,730-14,654 (-89.44%)0.00%$0 MNov 4, 2026
33TD Waterhouse Canada Inc.1,5000 (0.00%)0.00%$0 MOct 16, 2026
34Sterling Capital Management LLC1,144+1,022 (+837.70%)0.00%$0 MOct 22, 2026
35FMR LLC1,126-3,074 (-73.19%)0.00%$0 MNov 10, 2026
36California State Teachers Retirement System3910 (0.00%)0.00%$0 MNov 13, 2026
37PNC Financial Services Group, Inc.220New0.00%$0 MNov 6, 2026
38GAMMA Investing LLC174+39 (+28.89%)0.00%$0 MOct 8, 2026
39Physician Wealth Advisors, Inc.830 (0.00%)0.00%$0 MOct 20, 2026
40Fortitude Family Office, LLC83New0.00%$0 MOct 14, 2026
41Allworth Financial LP66+51 (+340.00%)0.00%$0 MNov 17, 2026
42Arax Advisory Partners58-21 (-26.58%)0.00%$0 MNov 12, 2026
43Root Financial Partners, LLC47New0.00%$0 MOct 21, 2026
44Osaic Holdings, Inc.22-2 (-8.33%)0.00%$0 MNov 12, 2026
45Caitong International Asset Management Co., Ltd12New0.00%$0 MOct 29, 2026
46Transamerica Financial Advisors, LLC110 (0.00%)0.00%$0 MNov 12, 2026
47Farther Finance Advisors, LLC10-3 (-23.08%)0.00%$0 MOct 8, 2026
48EverSource Wealth Advisors, LLC50 (0.00%)0.00%$0 MNov 4, 2026
49Rothschild Investment LLC1-3 (-75.00%)0.00%$0 MNov 10, 2026
50SJS Investment Consulting Inc.1New0.00%$0 MOct 26, 2026

Mutual funds holding CapsoVision, Inc.#

60 funds hold shares worth $25 M (about 6.4% of the company). Since their previous reports 46 added shares and 9 sold, buying $6 M net.
Mutual funds holding CapsoVision, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.925,200$7 M1.7%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors825,385$6 M1.5%<0.01%+39%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC381,157$3 M0.71%<0.01%+38%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors315,596$2 M0.59%0.02%+112%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.142,359$1 M0.27%<0.01%+412%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors114,619$1 M0.21%0.06%+63%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.100,983$1 M0.19%<0.01%+55%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.85,030$1 M0.16%<0.01%+39%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC62,155$0 M0.12%<0.01%+585%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC46,011$0 M0.09%<0.01%+39%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC36,706$0 M0.07%<0.01%+39%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC32,592$0 M0.06%0.02%+126%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC30,790$0 M0.06%<0.01%+24%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC29,810$0 M0.06%<0.01%+1.8%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation25,800$0 M0.05%<0.01%+1073%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.18,030$0 M0.03%<0.01%+32%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.16,307$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.15,978$0 M0.03%<0.01%−18%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.17,618$0 M0.03%<0.01%+406%May 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC16,675$0 M0.03%<0.01%+38%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.11,929$0 M0.02%<0.01%+24%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC10,872$0 M0.02%<0.01%+55%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company11,520$0 M0.02%<0.01%+440%May 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC9,461$0 M0.02%<0.01%−2.4%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC10,476$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC9,003$0 M0.02%<0.01%+64%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC8,879$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC7,651$0 M0.01%0.03%+58%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS7,550$0 M0.01%<0.01%+46%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.6,927$0 M0.01%<0.01%+595%May 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.5,499$0 M0.01%<0.01%+42%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC5,324$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.5,321$0 M<0.01%<0.01%+82%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC6,064$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC5,109$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,071$0 M<0.01%<0.01%+112%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC4,999$0 M<0.01%<0.01%+56%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC4,525$0 M<0.01%<0.01%+50%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC4,085$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC3,243$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC3,116$0 M<0.01%0.02%+94%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,384$0 M<0.01%<0.01%+60%Jul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC2,771$0 M<0.01%<0.01%+32%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,183$0 M<0.01%<0.01%−2.9%Jul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC2,524$0 M<0.01%<0.01%+39%Jun 30, 2026
🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC2,686$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC2,668$0 M<0.01%<0.01%+72%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management2,279$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.2,493$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC1,400$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC1,400$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,312$0 M<0.01%<0.01%+429%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,179$0 M<0.01%<0.01%+186%Jun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,011$0 M<0.01%<0.01%−41%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,038$0 M<0.01%<0.01%+193%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,025$0 M<0.01%<0.01%+191%May 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC829$0 M<0.01%<0.01%+5.1%Jun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.662$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC662$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.107$0 M<0.01%<0.01%+463%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 60 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at CapsoVision, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$16.0 M
6 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$16.0 M
open market only
Insiders on file
11
since
$15.0 M$0Jun 2026: bought $102 K (1 trades), sold $0 (0 trades)Jun 26Jul 2026: bought $906 K (2 trades), sold $0 (0 trades)JulSep 2026: bought $15.0 M (3 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
CapsoVision, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Eliyahou Harari10% ownerBuyindirect+878,735$5.690$5.0 M1.40 MForm 4
filed Eliyahou Harari10% ownerBuyindirect+878,734$5.690$5.0 M878,734Form 4
filed Ching Hang Shen10% ownerBuyindirect · amended+878,734$5.690$5.0 M7.28 MForm 4/A
filed Ching Hang Shen10% ownerBuyindirect+878,734$5.690$5.0 M2.93 MForm 4
filed Eliyahou Harari10% ownerBuyindirect+61,068$6.730$411 K3.34 MForm 4
filed Eliyahou Harari10% ownerBuyindirect+81,300$6.090$495 K3.28 MForm 4
filed Hui Ying KuoDirectorOption exercise+2,022$7.580$15 K15,263Form 4
filed Julia S. GouwDirectorOption exercise+2,022$7.580$15 K4,909Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: CapsoVision, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.0 M
4.2% of shares · 14.33 days to cover
Shares sold short, last 24 reportsAll stocks →

IPO: priced at $5.00, raising $27.5M · IPO calendar

Trading halts

  • 2025-12-19 20:55 UTC, code LUDP, resumed 21:00 UTC
  • 2025-12-09 16:26 UTC, code LUDP, resumed 16:36 UTC
  • 2025-07-02 19:57 UTC, code LUDP, resumed 20:00 UTC

Fails to deliver

  • : 136 shares at $6.94
  • : 5 shares at $7.06
  • : 1,423 shares at $6.80
  • : 43 shares at $6.64
  • : 2,066 shares at $6.78

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

CapsoVision, Inc. scorecard#

Passes 3 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median28.1×Price to book 28.1× against Medical Devices's median of 2.5×.
    • ✗Price to sales below its peers' median26.8×Price to sales 26.8× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%-6.2%Free cash flow is -6.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • ✓Revenue grew in the newest year15.2%Revenue up 15.2% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.03 vs -9.85Diluted EPS -1.03 in fiscal 2025 against -9.85 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$25 MNet income -$25 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-188.3%-188.3% against Medical Devices's median of -8.2% (86 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.76 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • ✓Altman Z-score outside the distress zone30.47Z-score 30.47 (safe zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from CapsoVision, Inc.'s statements, beside the median of Medical Devices.

CapsoVision, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-188.3%-8.2%
Net margin-186.9%-10.4%
Revenue growth15.2%10.4%
Free cash flow margin-169.4%-1.9%

2of 8on the Piotroski tests of financial strength

  • Net loss of $25 million.
  • Free cash flow was negative: -$23 million.

CapsoVision, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CapsoVision, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024
Income statement
Revenue1412
Cost of revenue6.45.4
Gross profit7.26.4
Research and development1815
Selling and marketing7.57.0
General and administrative6.84.2
Operating expenses3326
Operating income−26−20
Other non-operating income (expense)0.20.0
Income before tax−25−20
Income tax0.00.0
Net income attributable to shareholders−25−20
Earnings per share, basic-1.03-9.85
Earnings per share, diluted-1.03-9.85
Shares, weighted average (basic)252.0
Shares, weighted average (diluted)252.0
Balance sheet
Receivables2.52.0
Inventory3.02.6
Other current assets0.40.3r
Current assets1715
Property, plant and equipment0.60.7
Right-of-use (leased) assets0.81.2
Total assets1817
Accounts payable1.10.7
Current liabilities4.41.8
Lease liabilities (non-current)0.50.9
Total liabilities4.92.7
Retained earnings−156−130
Shareholders' equity13−130
Total liabilities and equity1817
Shares outstanding472.1
Cash-flow statement
Depreciation and amortization0.20.2
Share-based compensation0.80.2
Cash from operating activities−23−20
Capital expenditure−0.1−0.2
Cash from investing activities−0.1−0.2
Cash from financing activities2415
Report10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What CapsoVision, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Services(total)$1 M6.8%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at CapsoVision, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 6 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 7

CapsoVision, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Material agreementResults announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share saleResults announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Material agreementBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

10 private funding rounds before listing

Private share sales · funding history

Private share sales of CapsoVision, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2019$65 MNo. 10$50 to $250 million114equitySEC
Aug 2018$6 MNo. 9$2 to $10 million11equitySEC
Jan 2018$8 MNo. 8$2 to $10 million8equitySEC
Mar 2016$5 MNo. 7$2 to $10 million9equitySEC
Jan 2014$16 MNo. 6$10 to $50 million6equitySEC
Oct 2012$4 MNo. 5$2 to $10 million4equity, optionsSEC
Dec 2011$1 MNo. 4Under $2 million8equitySEC
Jan 2011$3 MNo. 3$2 to $10 million14equitySEC
Feb 2010$3 MNo. 2$2 to $10 million7equitySEC
Jul 2009$1 MNo. 1Under $2 million4equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at CapsoVision, Inc.#

2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $105 K a year.

Certified, FY2025
2
#1,645 among companies on value.today
Worker positions
2
Median wage offered
$105 K
a year, full-time
Applications filed
2
CapsoVision, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
QA/RA SpecialistBioengineers and Biomedical Engineers1$85 K
Software EngineerSoftware Developers1$125 K

Where: Saratoga, CA 2

CapsoVision, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202522$105 K2
FY202455$85 K5
FY202222$107 K2
FY202111$62 K1
FY202011$135 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as CapsoVision, Inc.

How CapsoVision, Inc. compares in Medical Devices

  • Market cap$372 M · higher than 45% of 142
  • Revenue$14 M · higher than 19% of 155
  • Net margin-210.3% · higher than 6% of 144
  • Revenue growth15.2% · higher than 60% of 104
  • Price / sales26.8× · lower than 0% of 96
  • Price / book28.1× · lower than 2% of 99
  • FCF yield-6.2% · higher than 37% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
CapsoVision, Inc.🇺🇸$372 M—-210.3%+15.2%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CapsoVision, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CapsoVision, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CapsoVision, Inc.? Suggest a correction